Publications2023-08-23T10:08:45-04:00

AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport

Samal K, Zhao P, McClung H, Gerner EW, Bachmann AS, Saulnier Sholler G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine[...]

Abstract|

A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of Cancer Therapy

Saulnier Sholler G, Ferguson W, Bergendahl G, Currier E, Lenox SR, Bond J, Slavik M, Roberts W,  Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna [...]

Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention

Bachmann AS, Geerts D, Saulnier Sholler G: Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention, In: Pediatric Cancer, Volume 1, Neuroblastoma: Diagnosis, Therapy, and Prognosis, Ed. Hayat MA, Springer,[...]

AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport

Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Saulnier Sholler G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma[...]

Phase I Trial of TPI 287 as a Single Agent and in Combination with Temozolomide (TMZ) in Patients with Refractory or Recurrent Neuroblastoma (NB) or Medulloblastoma (MB)

Saulnier Sholler G, Eslin D, Roberts W, Kaplan J, Bergendahl G, Higgins T, Ashikaga T, Lenox S, Silberman S, Ferguson W. Phase I Trial of TPI 287 as a Single Agent[...]

Abstract|
Go to Top